25 July 2012
Scientists have unveiled a new pill which they claim could hold the key to treating a number of neurological disorders.
Experts at Northwestern University in Chicago assert that the MW151 can help people living with multiple sclerosis (MS), Parkinson's and Alzheimer's, and in the case of the latter disease may even permanently halt the development of the condition.
In a study published in the Journal of Neuroscience, scientists revealed that early treatment with MW151 halted the progression of Alzheimer's and may offer a novel way of treating a range of conditions by targeting the accumulation of beta amyloid protein deposits that lead to neurological disorders.
Study author Dr Linda Van Eldik, director of the Sanders-Brown Centre on Aging at the University of Kentucky, said the drug protected against the damage associated with learning and memory impairment., and suggested that giving this drug before Alzheimer's memory changes are at a late stage may be a "promising future" approach to therapy.
Professor Mark Wainright, another study author, from Northwestern's Feinberg School, added: "If you took a drug like this early on after traumatic brain injury or even a stroke, you could possibly prevent the long-term complications of that injury including the risk of seizures, cognitive impairment, and, perhaps, mental health issues."
The pill is now undergoing phase I clinical testing on human subjects, with the results due for release in the near future.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.